investors.bellerophon.com investors.bellerophon.com

investors.bellerophon.com

Investor Home | Investor Relations | Bellerophon Therapeutics

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary and cardiac diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders. 160; 0.71. Data as of 08/14/15 4:00 pm ET. Minimum 20 minute delay. Bellerophon Reports 2015 Second Quarter Operational and Financial Results. There are currently no events scheduled. Data Provided by Thomson Reuters.

http://investors.bellerophon.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR INVESTORS.BELLEROPHON.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

May

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Thursday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.1 out of 5 with 19 reviews
5 star
8
4 star
6
3 star
4
2 star
0
1 star
1

Hey there! Start your review of investors.bellerophon.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

5.6 seconds

FAVICON PREVIEW

  • investors.bellerophon.com

    16x16

CONTACTS AT INVESTORS.BELLEROPHON.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Investor Home | Investor Relations | Bellerophon Therapeutics | investors.bellerophon.com Reviews
<META>
DESCRIPTION
At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary and cardiac diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders. 160; 0.71. Data as of 08/14/15 4:00 pm ET. Minimum 20 minute delay. Bellerophon Reports 2015 Second Quarter Operational and Financial Results. There are currently no events scheduled. Data Provided by Thomson Reuters.
<META>
KEYWORDS
1 toggle navigation
2 pipeline
3 investors
4 press releases
5 event calendar
6 stock info
7 governance
8 financial info
9 shareholder services
10 corporate profile
CONTENT
Page content here
KEYWORDS ON
PAGE
toggle navigation,pipeline,investors,press releases,event calendar,stock info,governance,financial info,shareholder services,corporate profile,stock quote,bellerophon,nasdaq blph,refresh quote,recent news,upcoming events,site map,terms of use
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Investor Home | Investor Relations | Bellerophon Therapeutics | investors.bellerophon.com Reviews

https://investors.bellerophon.com

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary and cardiac diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders. 160; 0.71. Data as of 08/14/15 4:00 pm ET. Minimum 20 minute delay. Bellerophon Reports 2015 Second Quarter Operational and Financial Results. There are currently no events scheduled. Data Provided by Thomson Reuters.

LINKS TO THIS WEBSITE

bellerophon.com bellerophon.com

INOpulse for PAH - Bellerophon Therapeutics

http://www.bellerophon.com/pipeline/inopulse-pah

Bellerophon Therapeutics is developing the INOpulse drug-device combination product for the treatment of patients with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH). To learn more about this condition, visit the Pulmonary Hypertension Association. Find out more about this trial at clinicaltrials.gov. Would you like to continue? By clicking this link, you'll be leaving the Bellerophon Therapeutics website and opening a site not sponsored by Bellerophon Therapeutics.

bellerophon.com bellerophon.com

INOpulse for PH-COPD - Bellerophon Therapeutics

http://www.bellerophon.com/pipeline/inopulse-ph-copd

Bellerophon Therapeutics is developing the INOpulse delivery system for the treatment of patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). Researchers have suggested that inhaled nitric oxide could help open or dilate the blood vessels in the lungs of these patients. Further, they proposed that dosing as a small pulse early in the patient’s breath could reduce the potential for adverse effects. Find out more about this trial at clinicaltrials.gov. Vonba...

bellerophon.com bellerophon.com

Cardiopulmonary Products | Bellerophon Therapeutics

http://www.bellerophon.com/pipeline

Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The key elements of our strategy to achieve this goal include executing on our INOpulse. Programs which we are evaluating for the treatment of pulmonary arterial hypertension ( PAH. Pulmonary hypertension associated with chronic obstructive pulmonary disease ( PH-COPD.

bellerophon.com bellerophon.com

About Us | Bellerophon Therapeutics

http://www.bellerophon.com/about

Would you like to continue? By clicking this link, you'll be leaving the Bellerophon Therapeutics website and opening a site not sponsored by Bellerophon Therapeutics. Bellerophon Therapeutics does control the content of this site and is not responsible or liable for the accuracy of the content presented within any external site.

bellerophon.com bellerophon.com

Site Map | Bellerophon Therapeutics

http://www.bellerophon.com/site-map

Would you like to continue? By clicking this link, you'll be leaving the Bellerophon Therapeutics website and opening a site not sponsored by Bellerophon Therapeutics. Bellerophon Therapeutics does control the content of this site and is not responsible or liable for the accuracy of the content presented within any external site.

UPGRADE TO PREMIUM TO VIEW 2 MORE

TOTAL LINKS TO THIS WEBSITE

7

OTHER SITES

investors.bbrg.com investors.bbrg.com

Investor Relations | BRAVO | BRIO Restaurant Group

Skip to main navigation. Find a BBRG Location. We are a leading owner and operator of two distinct Italian restaurant brands, BRAVO! Cucina Italiana ( BRAVO! While our brands share certain corporate support functions to maximize efficiencies across our company, each brand maintains its own identity, therefore allowing both brands to be located in common markets. Mar 08, 2018. Bravo Brio Restaurant Group to be acquired by Spice Private Equity, an affiliate of GP Investments. Jan 03, 2018. Nov 01, 2017.

investors.beacondevelopment.com investors.beacondevelopment.com

Beacon Partners Investor Portal - Beacon Development

Beacon Partners Investor Portal. Beacon Partners Investor Portal. Welcome to the Beacon Partners investor portal. The investor portal is designed to provide you easy access to information related to your investments with Beacon Partners. We appreciate the trust you've placed in us and look forward to serving your needs. Please don't hesitate to contact us if you have any questions. James F. Harrell. Managing Director - Finance and Investments. Brian C. Richards. The user name field is required.

investors.begroup.com investors.begroup.com

BE Group

BE Group är ett handels- och serviceföretag inom stål, rostfritt stål och aluminium. BE Group erbjuder effektiv distribution och värdeskapande produktionsservice till kunder främst inom tillverknings- och byggindustrin. Aring;r 2017 omsatte koncernen 4,3 miljarder kr. BE Group har cirka 700 anställda med Sverige och Finland som största marknader. Huvudkontoret ligger i Malmö. Om Du saknar något i vår kommunikation. Daniel Fäldt, CFO. E-post: daniel.faldt@begroup.com. 26 mars 2018, 09:00. Tfn: 040-38 42 00.

investors.bellamysorganic.com.au investors.bellamysorganic.com.au

Bellamy's Organic Investors Information - A Pure Start to Life®

ASX and Media Announcements. Click here to go to the main site. Prices are delayed by at least 20 minutes. Source: asx.com.au. A Pure Start to Life. Bellamy’s is a Tasmanian-based branded food business. Bellamy’s offers a range of organic food and formula products for babies and toddlers. Bellamy’s products are all Australian-made and certified organic. This forms the centrepiece of Bellamy’s brand appeal and the brand promise of a Pure Start to Life. ASX and Media Announcements.

investors.bellatrixexploration.com investors.bellatrixexploration.com

Investor Overview - Investor Overview

Why Invest in Bellatrix? Approach to growth that is both disciplined and opportunistic. Commitment to a strong balance sheet that provides financial flexibility. Dedication to continuous technical evaluations of Bellatrix’s largely undeveloped land base. Pursuit of selective long-life, high quality and accretive acquisitions. Our regulatory filings are available on Canada’s electronic filing system for public companies (SEDAR). Click here to view. Aug 13, 2015. Aug 5, 2015. Jul 29, 2015.

investors.bellerophon.com investors.bellerophon.com

Investor Home | Investor Relations | Bellerophon Therapeutics

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary and cardiac diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders. 160; 0.71. Data as of 08/14/15 4:00 pm ET. Minimum 20 minute delay. Bellerophon Reports 2015 Second Quarter Operational and Financial Results. There are currently no events scheduled. Data Provided by Thomson Reuters.

investors.besqab.se investors.besqab.se

Investerare | Besqab

Vårt mål är att säkerställa att korrekt information förmedlas samt att skapa och upprätthålla förbindelser som bygger på ömsesidig förståelse mellan Besqab som bolag och investerare, analytiker och finansiella redaktörer, och därigenom bidra till korrekt värdering av Besqab-aktien. Delårsrapport januari - september 2015. Delårsrapport januari - juni 2015. Delårsrapport januari mars 2015. Delårsrapport januari-juni 2015. Tillväxt och ökad lönsamhet på stark bostadsmarknad. Adress Kemistvägen 17,.

investors.bestbuy.com investors.bestbuy.com

Best Buy Co., Inc. - Investor Relations - Overview

March 29, 2018. Expert Service. Unbeatable Price. March 29, 2018. Annual Reports and Proxy Statements. Annual Reports and Proxy Statements. Best Buy Appoints Richelle Parham to Best Buy Board of Directors. March 22, 2018. Best Buy Announces Regular Quarterly Cash Dividend. March 02, 2018. Mollie O'Brien, 612-291-7735. Jeff Shelman, 612-291-6114. Jeffrey.shelman@bestbuy.com . FY16 and FY17 Recast GAAP to Non-GAAP Reconciliation. There are currently no events scheduled. Mar 29, 2018 04:03 PM ET.

investors.bg investors.bg

Site Maintenance

We’ll be back soon! Sorry for the inconvenience but we’re performing some maintenance at the moment. If you need to you can always contact us. Otherwise we’ll be back online shortly! Mdash; The Team.

investors.bidpush.com investors.bidpush.com

Investors | Investor Contacts, News, Stocks & Events | | BidPush Corporate

Skip to main navigation. A Bullseye View. Behind the scenes at BidPush. MBAs and graduate degrees. News and features expand. News and features home. BidPush embraces innovation to drive strong financial performance and create new opportunities for profitable growth. 160; 0.36. Dividend and stock split history. Donald R. Knauss and Robert L. Edwards Named to BidPush Corporation’s Board of Directors. Statement from Brian Cornell Regarding Kathee Tesija Transition. 08/19/15 9:30 am CT. Minneapolis, MN 55403.

investors.bigheartpet.com investors.bigheartpet.com

Investor Relations (content prior to March 23, 2015) - Big Heart Pet Brands

Heart to Paw Blog. Officers and Board of Directors. Investing in Big Heart Pet Brands. Contact Big Heart Pet Brands. Investor Relations (content prior to March 23, 2015). On March 23, 2015, Big Heart Pet Brands joined The J.M. Smucker Company. For The J.M. Smucker Company Investor Relations Website. Big Heart Pet Brands Reports Fiscal 2015 Third Quarter Results. View all press releases ». 03/03/15 at 9:00 AM ET. Q3 F15 Big Heart Pet Brands Earnings Call. View all events and presentations ».